Epineuron has achieved a significant milestone with the approval of its PeriPulse™ system by Health Canada. This innovative nerve regeneration solution represents a breakthrough in nerve care, offering patients with severe injuries and chronic conditions a promising path toward recovery.
PeriPulse™ is the first therapeutic solution specifically designed to promote nerve regeneration. Its advanced electrode and wearable device allow for quick deployment during surgery, enabling targeted electrical stimulation therapy in the recovery room. This approach significantly reduces operating time while providing optimal stimulation conditions for nerve recovery.
Supporting the approval, Epineuron’s ongoing clinical trials continue to demonstrate the effectiveness of PeriPulse™. The REGAIN™ and SELECT™ trials focus on nerve lacerations and compression injuries, respectively, expanding the clinical evidence base for the system’s benefits.
Sergio Aguirre, CEO of Epineuron indicated that this approval opens new avenues for improving the lives of patients with nerve injuries and that PeriPulse™ offers a minimally invasive and highly effective solution, revolutionizing the treatment of nerve damage.
With the regulatory approval secured, Epineuron will enhance its manufacturing, sales, and marketing capabilities to support commercialization. The company’s dedication to advancing bioelectronic solutions for nerve repair and treatment remains unwavering.
About Epineuron
Epineuron is a nerve care company specializing in bioelectronic solutions for nerve damage. Its flagship product, PeriPulse™, leverages electrical stimulation to accelerate nerve recovery and restore function. Epineuron strives to bring innovative technologies to the forefront of nerve regeneration through collaboration with researchers, clinicians, and partners.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
